CAMZYOS® 
(mavacamten)
Healthcare Professional Guide
▼CAMZYOS is subject to additional monitoring to quickly identify new safety information.
Healthcare professionals are asked to report any suspected adverse events.
This website contains specific information on the safe prescribing and use of CAMZYOS (mavacamten).
This website contains the following information:
- Details on the mechanism of action of CAMZYOS and dosing information
- Details on the risks of
- Heart failure due to systolic dysfunction
- Heart failure due to drug interactions
- Embryo-fetal toxicity
- Information about educational materials that healthcare professionals (HCPs) should distribute to patients and/or their caregiver(s)
- Contact details for reporting adverse events and pregnancies in patients receiving CAMZYOS and where to find additional information
- A Treating and Counseling Checklist to ensure that HCPs, patients and/or their caregiver(s) are aware of the steps they need to take for safe use of CAMZYOS.
- For the Taiwan Food and Drug Administration (TFDA) approved package insert, please refer to the following QR codes.
